FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2011961498> ?p ?o ?g. }

• W2011961498 abstract "The only effective medical treatment of symptomatic uterine leiomyomas has been the gonadotropin-releasing hormone agonist leuprolide acetate depot, which carries a risk of producing hypoestrogenic symptoms. High-dose progestin therapy has been used to control heavy uterine bleeding (HUB) but may cause breakthrough bleeding. Another option is asoprisnil, a selective progesterone (P) receptor modulator that has mixed P agonist and antagonist actions and is highly uterine-selective. In both primate and human studies, it has induced amenorrhea and suppressed endometrial growth. This randomized prospective, double-blind, placebo-control study, carried out at 28 sites in the United States and 1 in Canada, enrolled 129 women 18 to 49 years of age who had at least one leiomyoma measuring 3 cm or more in diameter or multiple small lesions producing a uterine volume exceeding 200 cm 3 . All participants had normal menses and no other significant pelvic pathology. They received either asoprisnil in a daily oral dose of 5, 10, or 25 mg or a placebo for 12 weeks. Uterine bleeding was monitored by daily diaries, and uterine volume was measured sonographically. The 5-, 10-, and 25-mg doses of asoprisnil suppressed uterine bleeding in 28%, 64%, and 83% of patients, respectively. These patients did not have even light bleeding while being treated. No placebo recipient responded. Dose-related rates of amenorrhea, defined as no bleeding or only spotting, were 16%, 36%, and 70%, respectively. Compared with placebo, treatment with 25 mg daily for 4 and 8 weeks was associated with a statistically significant decrease in leiomyoma volume, and by week 12 it was reduced by 36%. The higher doses of asoprisnil significantly reduced bloating and, in patients given 25 mg daily, pelvic pressure also declined significantly by week 12. Hemoglobin concentrations increased significantly more in all treatment groups than in placebo recipients. Treatment had no apparent effect on pelvic pain or dyspareunia. Hypoestrogenic symptoms were minimal. Endometrial thickness was similar in the treatment and placebo groups at the end of the study, and no hyperplasia or other adverse changes were observed. Asoprisnil therapy appeared to inhibit basal gonadotropin concentrations. There were no clinically significant changes in blood chemistry or blood pressure, and no clinically relevant cervical abnormalities were observed. Adverse effects of all types were similarly frequent in the treatment and placebo groups. These findings support the use of asoprisnil to treat complaints related to uterine leiomyomas, notably HUB and bulk-related symptoms, without significantly altering blood estrogen levels at the same time. Treatment with doses as high as 25 mg daily for 12 weeks was well tolerated." @default.
• W2011961498 created "2016-06-24" @default.
• W2011961498 creator A5021739652 @default.
• W2011961498 creator A5026462899 @default.
• W2011961498 creator A5029752262 @default.
• W2011961498 creator A5076507685 @default.
• W2011961498 creator A5083839550 @default.
• W2011961498 creator A5088324465 @default.
• W2011961498 date "2007-10-01" @default.
• W2011961498 modified "2023-09-25" @default.
• W2011961498 title "A Randomized, Controlled Trial of Asoprisnil, a Novel Selective Progesterone Receptor Modulator, in Women With Uterine Leiomyomata" @default.
• W2011961498 doi "https://doi.org/10.1097/01.ogx.0000282008.71463.a2" @default.
• W2011961498 hasPublicationYear "2007" @default.
• W2011961498 type Work @default.
• W2011961498 sameAs 2011961498 @default.
• W2011961498 citedByCount "0" @default.
• W2011961498 crossrefType "journal-article" @default.
• W2011961498 hasAuthorship W2011961498A5021739652 @default.
• W2011961498 hasAuthorship W2011961498A5026462899 @default.
• W2011961498 hasAuthorship W2011961498A5029752262 @default.
• W2011961498 hasAuthorship W2011961498A5076507685 @default.
• W2011961498 hasAuthorship W2011961498A5083839550 @default.
• W2011961498 hasAuthorship W2011961498A5088324465 @default.
• W2011961498 hasConcept C121608353 @default.
• W2011961498 hasConcept C126322002 @default.
• W2011961498 hasConcept C126894567 @default.
• W2011961498 hasConcept C141071460 @default.
• W2011961498 hasConcept C142724271 @default.
• W2011961498 hasConcept C170493617 @default.
• W2011961498 hasConcept C204787440 @default.
• W2011961498 hasConcept C27081682 @default.
• W2011961498 hasConcept C2776363309 @default.
• W2011961498 hasConcept C2776607906 @default.
• W2011961498 hasConcept C2777230143 @default.
• W2011961498 hasConcept C2777795800 @default.
• W2011961498 hasConcept C2778058571 @default.
• W2011961498 hasConcept C2778938600 @default.
• W2011961498 hasConcept C2779066055 @default.
• W2011961498 hasConcept C2779093440 @default.
• W2011961498 hasConcept C2779234561 @default.
• W2011961498 hasConcept C2779279991 @default.
• W2011961498 hasConcept C2780159708 @default.
• W2011961498 hasConcept C29456083 @default.
• W2011961498 hasConcept C3017725331 @default.
• W2011961498 hasConcept C530470458 @default.
• W2011961498 hasConcept C54355233 @default.
• W2011961498 hasConcept C71315377 @default.
• W2011961498 hasConcept C71924100 @default.
• W2011961498 hasConcept C84606932 @default.
• W2011961498 hasConcept C86803240 @default.
• W2011961498 hasConcept C98717036 @default.
• W2011961498 hasConceptScore W2011961498C121608353 @default.
• W2011961498 hasConceptScore W2011961498C126322002 @default.
• W2011961498 hasConceptScore W2011961498C126894567 @default.
• W2011961498 hasConceptScore W2011961498C141071460 @default.
• W2011961498 hasConceptScore W2011961498C142724271 @default.
• W2011961498 hasConceptScore W2011961498C170493617 @default.
• W2011961498 hasConceptScore W2011961498C204787440 @default.
• W2011961498 hasConceptScore W2011961498C27081682 @default.
• W2011961498 hasConceptScore W2011961498C2776363309 @default.
• W2011961498 hasConceptScore W2011961498C2776607906 @default.
• W2011961498 hasConceptScore W2011961498C2777230143 @default.
• W2011961498 hasConceptScore W2011961498C2777795800 @default.
• W2011961498 hasConceptScore W2011961498C2778058571 @default.
• W2011961498 hasConceptScore W2011961498C2778938600 @default.
• W2011961498 hasConceptScore W2011961498C2779066055 @default.
• W2011961498 hasConceptScore W2011961498C2779093440 @default.
• W2011961498 hasConceptScore W2011961498C2779234561 @default.
• W2011961498 hasConceptScore W2011961498C2779279991 @default.
• W2011961498 hasConceptScore W2011961498C2780159708 @default.
• W2011961498 hasConceptScore W2011961498C29456083 @default.
• W2011961498 hasConceptScore W2011961498C3017725331 @default.
• W2011961498 hasConceptScore W2011961498C530470458 @default.
• W2011961498 hasConceptScore W2011961498C54355233 @default.
• W2011961498 hasConceptScore W2011961498C71315377 @default.
• W2011961498 hasConceptScore W2011961498C71924100 @default.
• W2011961498 hasConceptScore W2011961498C84606932 @default.
• W2011961498 hasConceptScore W2011961498C86803240 @default.
• W2011961498 hasConceptScore W2011961498C98717036 @default.
• W2011961498 hasLocation W20119614981 @default.
• W2011961498 hasOpenAccess W2011961498 @default.
• W2011961498 hasPrimaryLocation W20119614981 @default.
• W2011961498 hasRelatedWork W1999344589 @default.
• W2011961498 hasRelatedWork W2507295142 @default.
• W2011961498 hasRelatedWork W2902646137 @default.
• W2011961498 hasRelatedWork W3096266033 @default.
• W2011961498 hasRelatedWork W3124959669 @default.
• W2011961498 hasRelatedWork W4232411611 @default.
• W2011961498 hasRelatedWork W4239372735 @default.
• W2011961498 hasRelatedWork W4254873301 @default.
• W2011961498 hasRelatedWork W4293180940 @default.
• W2011961498 hasRelatedWork W2083697902 @default.
• W2011961498 isParatext "false" @default.
• W2011961498 isRetracted "false" @default.
• W2011961498 magId "2011961498" @default.
• W2011961498 workType "article" @default.